[go: up one dir, main page]

AU2001269927A1 - Thrombomodulin analogs for pharmaceutical use - Google Patents

Thrombomodulin analogs for pharmaceutical use

Info

Publication number
AU2001269927A1
AU2001269927A1 AU2001269927A AU6992701A AU2001269927A1 AU 2001269927 A1 AU2001269927 A1 AU 2001269927A1 AU 2001269927 A AU2001269927 A AU 2001269927A AU 6992701 A AU6992701 A AU 6992701A AU 2001269927 A1 AU2001269927 A1 AU 2001269927A1
Authority
AU
Australia
Prior art keywords
analogs
pharmaceutical use
thrombomodulin
thrombin
thrombomodulin analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269927A
Inventor
David Light
Michael John Morser
Mariko Nagashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001269927A1 publication Critical patent/AU2001269927A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.
AU2001269927A 2000-06-21 2001-06-20 Thrombomodulin analogs for pharmaceutical use Abandoned AU2001269927A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21367800P 2000-06-21 2000-06-21
US60/213,678 2000-06-21
US09/880,484 2001-06-12
US09/880,484 US6632791B1 (en) 2000-06-21 2001-06-12 Thrombomodulin analogs for pharmaceutical use
PCT/US2001/019590 WO2001098352A2 (en) 2000-06-21 2001-06-20 Thrombomodulin analogs for pharmaceutical use

Publications (1)

Publication Number Publication Date
AU2001269927A1 true AU2001269927A1 (en) 2002-01-02

Family

ID=26908302

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269927A Abandoned AU2001269927A1 (en) 2000-06-21 2001-06-20 Thrombomodulin analogs for pharmaceutical use

Country Status (10)

Country Link
US (2) US6632791B1 (en)
EP (1) EP1292673B1 (en)
JP (1) JP4855627B2 (en)
AT (1) ATE309339T1 (en)
AU (1) AU2001269927A1 (en)
DE (1) DE60114819T2 (en)
DK (1) DK1292673T3 (en)
ES (1) ES2256266T3 (en)
NO (1) NO20026147L (en)
WO (1) WO2001098352A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118580A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225255B2 (en) * 2002-05-01 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted antibodies as anticoagulants
US8012693B2 (en) 2003-12-16 2011-09-06 3M Innovative Properties Company Analysis of chemically crosslinked cellular samples
US7833978B2 (en) 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
EP1943332A4 (en) 2005-10-14 2011-04-13 Medimmune Inc Cell display of antibody libraries
EP2120049A1 (en) 2008-05-14 2009-11-18 PAION Deutschland GmbH Soluble thrombomodulin as a biomarker for treatments using anticoagulants
EP2320936A1 (en) * 2008-07-16 2011-05-18 PAION Deutschland GmbH Prevention and treatment of radiation injury
WO2010006635A1 (en) * 2008-07-16 2010-01-21 Paion Deutschland Gmbh Treatment of inflammatory bowel disease
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
WO2010142309A1 (en) * 2009-06-12 2010-12-16 Paion Deutschland Gmbh Treatment of coagulopathy with hyperfibrinolysis
CL2011001887A1 (en) 2010-08-05 2012-02-03 Council Scient Ind Res Chimeric protein constructs that possess anticoagulant and thrombolytic properties; nucleic acid sequence encoding them; vector; host cell; Preparation method; pharmaceutical formulation comprising them; and its use to inhibit thrombin.
WO2014020183A1 (en) * 2012-08-03 2014-02-06 Ici Immunochemical Intelligence Gmbh In-vitro assay for diagnosis of disorders of haemostasis
US9156904B2 (en) * 2013-07-29 2015-10-13 Blue Blood Biotech Corp. Thrombomodulin variants and use thereof
WO2017189943A1 (en) * 2016-04-28 2017-11-02 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
AU4533093A (en) * 1992-06-10 1994-01-04 Michael John Morser Mutants of the epidermal growth factor domains of human thrombomodulin

Also Published As

Publication number Publication date
EP1292673A2 (en) 2003-03-19
WO2001098352A3 (en) 2002-08-01
US20030186883A1 (en) 2003-10-02
ATE309339T1 (en) 2005-11-15
US6632791B1 (en) 2003-10-14
EP1292673B1 (en) 2005-11-09
NO20026147L (en) 2003-02-20
DK1292673T3 (en) 2006-03-27
JP4855627B2 (en) 2012-01-18
DE60114819T2 (en) 2006-08-10
JP2004527452A (en) 2004-09-09
WO2001098352A2 (en) 2001-12-27
NO20026147D0 (en) 2002-12-20
ES2256266T3 (en) 2006-07-16
DE60114819D1 (en) 2005-12-15
US6790828B2 (en) 2004-09-14

Similar Documents

Publication Publication Date Title
AU2001269927A1 (en) Thrombomodulin analogs for pharmaceutical use
AU2001292757A1 (en) Modified selex processes without purified protein
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2004041153A3 (en) Pharmaceutical composition including low dosages of desmopressin
YU12103A (en) Polymorphs of an epothilone analog
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2004024757A3 (en) Modified pna molecules
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
MXPA03007678A (en) Oral pharmaceutical composition of cefpodoxime proxetil.
MXPA03010549A (en) Oxcarbazepine dosage forms.
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
AU8738401A (en) Novel kallikrein gene
AU2924699A (en) Tryptase inhibitors
PL374080A1 (en) Processes for the preparation of fibrinogen
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES
MXPA04004090A (en) Substituted 1h-quinolin-2-one compounds.
UA83989C2 (en) Isolated peptide for promoting anti-tumor immune response, pharmaceutical composition based thereon and use thereof
IL151647A0 (en) Novel lhrh-antagonists, production and use thereof as medicament
HUP0301523A2 (en) Vegf peptides and their use for inhibiting angiogenesis
IL157026A0 (en) Crystal modification of a cyclic depsipeptide having improved strength
GB0221169D0 (en) Crystal
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
AU2003296543A1 (en) Peptides having a high cysteine content
DE60219601D1 (en) BY LIPOSOME-MEDIATED DNA ADMINISTRATION